Nuclear Chemistry

bio-betaNMR: A new tool to understand biology at the molecular level Although bNMR has been applied to nuclear physics and condensed matter for the past five decades, its application to biology, wet chemistry, and medicine are still fairy uncommon, mainly due to technical difficulties of maintaining liquid solutions under vacuum. Over the past three years, TRIUMF has not only pioneered technology that overcomes that barrier, but also carried out first experiments on liquids and biological samples, moving from proof-of-feasibility to first applications. In April 2017, we recorded the first-ever bNMR signals originating from oxygen and nitrogen coordinating Mg²⁺ in typical Mg complexes, illustrating that bNMR can discriminate between different structures. In July 2018, we carried out first bNMR measurements on Mg coordination to ATP. This achievement marks a milestone in applications of bNMR into biologically-relevant samples and opens new opportunities in the fields of wet chemistry, biology, and medicine.

Novel accelerator target technology for improved production of medical isotopes: Historically, research within TRIUMF’s Life Science division has focused on the world’s more common PET isotopes: ¹¹C, ¹³N and ¹⁸F. However, through new target development in recent years, this list has been dramatically expanded to include new isotopes through new target development: ⁶⁸Ga, ⁴⁴Sc, ⁸⁶Y, ⁸⁹Zr, ¹⁹²Ir, ⁵²Mn, ^61,64Cu, ^99mTc and ¹¹⁹Sb. One of these new target systems is the so-called solution target, modelled after the remotely-controlled ¹⁸F production process currently used in medical cyclotrons. In lieu of a traditional solid target station, this technique allows for the irradiation of solutions (for example: nitrate solutions of metals of interest) in a cost-efficient, simple, and safe manner.

Redefining the global isotope supply philosophy: In 2009, the world was recovering from widespread shortages of ^99mTc - an isotope used in ~40 million nuclear medicine scans around the world every year - when the Canadian federal government announced the imminent cessation of isotope production activities at the Chalk River reactor. In response, TRIUMF (along with BC Cancer, the Centre for Probe Development and Commercialization, and Lawson Health Research) teamed together to develop a novel, high-powered target hardware solution capable of enabling the production of commercial-scale quantities of ^99mTc using local, hospital-based cyclotrons. This technology has been licensed to a new spin-off company, ARTMS Products, Inc., which obtained US$3M in venture funding from Quark Ventures in December 2017. Cyclotron-produced ^99mTc is now being implemented in the United Kingdom, with additional jurisdictions soon to follow. This same hardware has since been adapted to allow for the production of ⁶⁸Ga, ⁶⁴Cu, ⁸⁹Zr and other isotopes of interest.